- PR Newswire•16 days ago
AUSTIN, Texas, Sept. 9, 2016 /PRNewswire/ -- ASPiRA LABs, a Vermillion company (VRML), today announced its support for the recent US Food and Drug Administration (FDA) safety communication which recommends against the use of any screening tests for ovarian cancer. Earlier this week, the FDA announced that it is alerting women about the risks associated with the use of tests being marketed as ovarian cancer screening tests.
- PR Newswire•18 days agoASPiRA LABs Partners with New York Yankees Manager Joe Girardi for Ovarian Cancer Awareness Campaign Promoting Earlier Diagnosis
"My mother, Angela, was a small Italian woman who was kind but tough on us about our education," said Girardi, who lost his mother to ovarian cancer while he was a student-athlete at Northwestern University. Ovarian cancer remains the deadliest cancer among women, with only a 46 percent chance of survival compared to 89 percent for breast cancer.
- PR Newswire•24 days agoVermillion, Inc. Kicks Off Ovarian Cancer Awareness Month by Ringing the NASDAQ Closing Bell with Olympic Gymnast Shannon Miller, and NASCAR Driver Martin Truex, Jr.'s Life Partner, Sherry Pollex
AUSTIN, Texas, Sept. 1, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, brings its ASPiRA LABs' OVA1® awareness team members, Olympic ...
Vermillion, Inc. (VRML)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Ask||4.00 x 100|
|Day's Range||1.30 - 1.37|
|52wk Range||0.92 - 2.20|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-3.71|
|Avg Vol (3m)||45,273|
|Dividend & Yield||N/A (N/A)|